|
Welcome
|
|
12 February 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | news |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
| [ ...Back to search results ] | [ Print-friendly version ] |
| A phase II/III randomised trial comparing Epirubicin, Cisplatin and Protracted Venous Infusion (PVI) 5-Fluorouracil (5-FU) (ECF), Epirubicin, Oxaliplatin and PVI 5-FU (EOF), Epirubicin, Cisplatin and Capecitabine (ECX) and Epirubicin, Oxaliplatin and Capecitabine (EOX) in Patients with Advanced Oesophago-Gastric Cancer |
| Source of record | UK Trials |
| ISRCTN | ISRCTN51678883 |
| Date ISRCTN assigned | 15/10/2002 |
| Local reference number(s) | MREC 01/2/31 |
| Public title | A phase II/III randomised trial comparing Epirubicin, Cisplatin and Protracted Venous Infusion (PVI) 5-Fluorouracil (5-FU) (ECF), Epirubicin, Oxaliplatin and PVI 5-FU (EOF), Epirubicin, Cisplatin and Capecitabine (ECX) and Epirubicin, Oxaliplatin and Capecitabine (EOX) in Patients with Advanced Oesophago-Gastric Cancer |
| Scientific title | |
| Acronym | The REAL-2 Study |
| Disease/condition/study domain | Advanced, oesophageal, oesophago-gastric junctional and gastric cancers. |
| Study hypothesis | To compare overall and progression free survival in patients treated with these four regimens principally comparing PVI 5FU versus Capecitabine and also Cisplatin versus Oxaliplatin. The aim is to demonstrate non-inferiority between these two main comparisons. |
| Design/methodology | Randomised controlled trial |
| Research ethics review | Not provided at time of registration |
| Countries of trial | United Kingdom |
| Participants - inclusion criteria | 1. Histologically verified locally advanced or metastatic adenocarcinoma, squamous cell carcinoma or undifferentiated carcinoma of the oesophagus, oesophago-gastric junction, or stomach. Patients with positive resection margin or tumour within 1mm of resection margin are eligible. 2. Uni-dimensionally measurable disease, as assessed by computed tomography (CT) and magnetic resonance imaging (MRI) scan in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines; evaluable disease, for example on oesophagogastroscopy. The only exception is patients with positive or close resection margins who will be evaluated for survival only. 3. No prior chemotherapy 4. No prior radiotherapy other than adjuvant where relapse is outside the radiotherapy fields 5. A glomerular filtration rate (GFR) of ≥60 ml/min by EDTA clearance or 24 hour urinary creatinine, investigator¿s discretion. Normal serum creatinine. 6. Serum bilirubin <2 x instiutional upper limit of normal range (IULNR) 7. Patients should have a projected life expectancy of at least 3 months 8. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 9. No history of other malignant diseases other than adequately treated non-melanotic skin cancer or in situ carcinoma of the uterine cervix 10. Adequate bone marrow function, white blood cell count (WBC) >3 x 10^9/l, neutrophils >1.5 x 10^9/l, platelets >100 x 10^9/l 11. Written informed consent |
| Participants - exclusion criteria | 1. Medical or psychiatric condition impairing the ability to give informed consent 2. Uncontrolled angina pectoris, heart failure, clinically significant uncontrolled cardiac arrhythmias, or clinically significant abnormal electrocardiogram (ECG) or cardiac history having a left ventricular ejection fraction (LVEF) of lower limit of normal range for institution as determined by multiple gated acquisition (MUGA) scan or echocardiogram 3. Any other serious uncontrolled medical conditions 4. Any pregnant or lactating woman. Any woman of child bearing potential must have a pregnancy test prior to randomisation and must take adequate precautions to prevent pregnancy during treatment. Any man with a partner of child bearing potential must take adequate precautions to prevent pregnancy during treatment. 5. Inability to complete the quality of life questionnaire |
| Patient information material | |
| Anticipated start date | 03/03/2000 |
| Anticipated end date | 14/11/2005 |
| Status of trial | Completed |
| Target number of participants | 1000 |
| Interventions | Treatment should commence within 28 days of baseline CT scan and may continue for up to 24 weeks with a maximum of 8 cycles of epirubicin, cisplatin or oxaliplatin. Patients are randomised to receive: 1. ECF Regimen (5-FU, Epirubicin and Cisplatin) 2. EOF Regimen (5-FU, Epirubicin and Oxaliplatin) 3. ECX Regimen (Capecitabine, Epirubicin and Cisplatin) 4. EOX Regimen (Capecitabine, Epirubicin and Oxaliplatin) |
| Primary outcome measure(s) | The primary endpoint of the study is overall survival. The study is powered to demonstrate non-inferiority of the 2 x 2 comparisons. |
| Secondary outcome measure(s) | 1. Response Rates 2.Toxicity 3. Duration of response and progression free survival 4. Quality of life 5. In the phase I part of the study, to establish the optimal dose of capecitabine in the regimens |
| Publications | Interim analyses: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15928658 Results: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=18172173 |
| Sources of funding | Prof Cunningham's Clinical Research Fund Roche Pharmaceuticals Research Grant Sanofi-Aventis Research Grant |
| Sponsor name | Royal Marsden Hospital (UK) |
| Sponsor details | Downs Road Sutton United Kingdom SM2 5PT |
| Sponsor telephone | +44 (0)20 8661 3156 |
| Sponsor fax | +44 (0)20 8643 9414 |
| Sponsor website | david.cunningham@rmh.nhs.uk |
| Contact name | Prof David Cunningham |
| Contact details | Royal Marsden Hospital Downs Road Sutton, Surrey United Kingdom SM2 5PT |
| Contact telephone | +44 (0)20 8661 3156 |
| Contact fax | +44 (0)20 8643 9414 |
| Contact email | david.cunningham@rmh.nhs.uk |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN51678883 |
| Date last extracted from ISRCTN register | 17/04/2008 |
|
|
|
|
|
| © 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement | |
|
|
|
|